Strikingly, the response of MYC-expressing hepatoblastoma cells to panobinostat was 10-times stronger than the one of Kras-driven tumor cells, whereas the antitumor effect of cisplatin and doxorubicin were comparable in both models (Fig. 4d). This evidence concerns the gene KRAS and hepatoblastoma.